Demographics of patients receiving TPOXX for treatment of monkeypox

Details

• Corporate Authors:
  National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of High-Consequence Pathogens and Pathology.
• Description:
  Updated August 31, 2022 ; CDC, in partnership with FDA, has made it easier for healthcare providers to provide tecovirimat (TPOXX) treatment to patients with monkeypox under an expanded access Investigational New Drug (EA-IND) protocol. As of August 29, 2022, CDC has received and abstracted data from forms submitted on 1001 patients. However, this number underestimates the number of patients who are receiving TPOXX treatment as healthcare providers can start treatment before submitting IND paperwork to CDC. The table below shows the demographics of these 1001 patients who have received TPOXX and whose data have been analyzed.
• Subjects:
  • Antiviral Agents
  • Drugs, Investigational
  • Mpox (monkeypox)
  • Poxviridae Infections/drug therapy
  • Smallpox/drug therapy
• Document Type:
  Webpage
• Corporate as Subject:
  Tecovirimat ; Tecovirimat
• Place as Subject:
  United States
• Download URL:
  https://stacks.cdc.gov/view/cdc/120812/cdc_120812_DS1.pdf
• File Type:
  [PDF - 144.56 KB]
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:3be55c350f66f00d8cdffc528a98de3494650f9ff56f69108d447b5684c5762d